Illinois requires insurance to cover EpiPens for kids

Amy Baxter | | Health Exec | Quality

Illinois became the first state to require insurance companies to pay the costs of EpiPen injection medicines for children 18 and younger. The law was signed into law by Gov. JB Pritzker and will take effect Jan. 1, 2020, CNN reported.

The new law comes at a time when the cost of the medication, which is used to treat life-threatening allergy reactions, has risen significantly. According to CNN, a pair of EpiPen injectors cost $100 in 2009 and cost $600 by 2016.

See the full story below:

Illinois just became the first state to require insurance companies to cover Ep…

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

FDA commissioner, a veteran cardiologist, highlights ongoing issues with US healthcare system
FDA commissioner urges health systems to strengthen AI quality oversight
The top 25 children's heart hospitals in the US
Study ranks US health system dead last among wealthy nations
The 25 top US hospitals for diabetes care
The 25 best heart hospitals in the United States

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.